Biosimilars in Oncology: Applications in Pharmaceutics and Pharmaceuticals
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Biopharmaceuticals".
Deadline for manuscript submissions: 20 April 2026 | Viewed by 3
Special Issue Editor
Interests: biosimilars; oncology; randomized controlled trials; pharmacokinetics; pharmacodynamics
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The development of biosimilar cancer treatments does not just offer direct cost savings, but also incentivises the evaluation and/or clinical use of new treatment approaches and novel drugs, as switching from a reference product to a biosimilar treatment is supported by most available data. Post-marketing pharmacovigilance programmes are therefore warranted. As such, in order to integrate biosimilars, for example, into oncology treatment, the logical consequence is to provide differing approval for biosimilar therapeutics with comparable efficacy and safety profiles for the recommended indications of their reference originator biologics. Because bioequivalence is not applicable to biological agents, compared with generics, biosimilars require more extensive analytical data to demonstrate their high similarity, which results in a longer development time and higher development costs for biosimilars.
Reference studies for the approval of biosimilar drugs typically consist of two parts: the primary objective is to show the equivalence of a biosimilar and reference drug in the pharmacokinetic subset (part 1) and their overall response (noninferior efficacy in the efficacy population) (part 2) during the combination phase. The result is their translation into clinical practice in single randomized controlled trials with different settings (neoadjuvant, adjuvant, and metastatic) based on reproducible efficacy data.
The aim of this Special Issue is to analyze the “world” of biosimilars in oncology with a particular focus on interdisciplinary research involving, but not limited to, biosimilars, oncology, pharmaceutical formulations, drug delivery, pharmacokinetics, biopharmaceutics, engineering, biomedical sciences, and cell biology, and also with a reference to pharmacoeconomic considerations.
Pharmaceutics invites submissions related to pharmaceutical formulation, process development, drug delivery, pharmacokinetics, and biopharmaceutics, while also encouraging contributions centred on drug discovery and development, medicinal chemistry, and pharmacology.
You may choose our Joint Special Issue in Pharmaceutics.
Dr. Jacopo Giuliani
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- biosimilars
- oncology
- randomized controlled trials
- pharmacokinetics
- pharmacodynamics
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
